Innovation Pharmaceuticals Inc (IPIX)

[kfcyahoo]

Sox,

True. What also adds time is the difference in outcome measures between the two trials.

P2a, 115 patients, 1 primary outcome measure(OM), 5 secondary OM.

P2b, 199 patients, 2 primary OMs, 9 secondary OM´s

199/115= 1.73, or 73% more patients

11/6= 1.8333, or 83% more outcome measures.

If they use the same staff as the P2a trial, we´re looking at ¨theoretically¨ ~30 weeks((1.78*17 weeks) I realize the comparison is not linear)).

Hopefully, the cro´s, or whoever is charged with the analysis, have more hands involved with P2b than the P2a trial, the wind picks up, and we sail out of these doldrums soon.